Drug Type Antibody drug conjugate (ADC) |
Synonyms Anti-CD117 amanitin ADC, Anti-CD117 amanitin antibody drug conjugate, CD117-amanitin antibody drug conjugate + [2] |
Mechanism RNA polymerase II inhibitors, c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 1 | US | 14 Feb 2022 | |
Lysosomal Storage Diseases | Phase 1 | US | 16 Feb 2019 | |
Anemia, Sickle Cell | Preclinical | - | - | |
Metabolic Diseases | Preclinical | - | - | |
Adult Acute Myeloblastic Leukemia | Discovery | US | 14 Feb 2022 | |
Anemia, Refractory, With Excess of Blasts | Discovery | US | 14 Feb 2022 | |
Acute Myeloid Leukemia | Discovery | US | 18 Oct 2020 |
NCT05223699 (ASH2022) Manual | Phase 1/2 | 4 | (chwcqqxtdh) = The remaining treatment-emergent AEs (TEAEs) were consistent with underlying disease and were considered unrelated to MGTA-117. TEAEs occurring at a frequency of >25% irrespective of causality included nausea, vomiting, tachycardia, thrombocytopenia, anemia, and liver enzyme elevation llzitmyrwf (wbqxhcbcir ) | Positive | 15 Nov 2022 |